PRECLINICAL STAGES OF ALZHEIMER’S DISEASE AND MILD COGNITIVE IMPAIRMENT MODELED WITH HESPEROS HUMAN-ON-A-CHIP® SYSTEM — Peer-reviewed publication in Alzheimer’s & Dementia: Translational Research & Clinical Interventions validates potential of drug discovery platform and ability to study early stages of disease pathology — ORLANDO, Fla. – May 28, 2020 – Hesperos Inc., pioneers of the Human-on-a-Chip® … Read more
HUMAN-ON-A-CHIP FOR RARE DISEASES DISCUSSION In our latest publication, UCF & Hesperos researchers discuss how Human-on-a-chip systems can be used to address the unique challenges facing rare diseases. Researchers cite that rare diseases are “limited by the high cost of research and low target population.” Further Discussion of Human-on-a-chip® technology Researchers further discuss how “Human-on-a-chip … Read more
Dr. Francis Collins, director of The National Institutes of Health, recently featured Hesperos technology on his blog. In the post, Dr. Collins reviews a published study where Hesperos researchers investigated and treated several cancer lines with existing chemotherapeutics. The study both treated the cancer while reproducing known toxic effects of specific drugs and their more … Read more
Hesperos, Inc., (www.hesperosinc.com) announced today the University of Central Florida (UCF) received the first phase of a $3.8 million milestone-based National Institutes of Health (NIH) grant for research involving the company’s human-on-a-chip system. “We are grateful to have funding to support research in an area that represents such a large and growing need,” said Dr. … Read more
HUMAN-ON-A-CHIP PREDICTS IN VIVO RESULTS BASED ON IN VITRO MODEL FOR THE FIRST TIME Hesperos’ integrated heart-liver Human-on-a-Chip® shown to correctly determine cardiotoxic mechanisms preclinically and replicate results seen in in vivo studies (ORLANDO, Fla.) — Hesperos Inc., pioneers of the “human-on-a-chip” in vitro system has announced the use of its innovative multi-organ model to successfully measure the concentration and metabolism of two known … Read more
In vitro multi-organ system by Hesperos, Inc. realistically replicates the responses of cancer treatments and has potential to inform treatment decisions. ORLANDO, FLA – June 19, 2019 — A reconfigurable “body-on-a-chip” model could transform drug development by simultaneously measuring compound efficacy and toxicity, for both target cells and other organs, such as the heart and … Read more
The interest in our human-on-a-chip model continues to grow. Last week we brought our systems to the National Center for Translational Science (NCATS) at the NIH in Washington, D.C. to perform a real-time demo using live cells. Hesperos, Inc. is the first company spun out from the Tissue Chip Program at NCATS. In attendance were … Read more
HESPEROS’ MULTI-ORGAN “HUMAN-ON-A-CHIP” SYSTEM FOUND EFFECTIVE FOR LONG-TERM TOXICOLOGY TESTING Collaboration between L’Oreal, Hesperos and UCF results in further reduction in reliance on animal testing in drug and cosmetics development (ORLANDO, Fla.) The replacement of animals as test subjects is one step closer to reality with the successful testing of multi-organ “human-on-a-chip” models to recapitulate … Read more
HESPEROS AT NCATS-NASA STATE-OF-THE-SCIENCE MEETING We’ve been forging new frontiers with our human-on-a-chip multi-organ models—could the next one take us into space? Last month, we traveled to Washington, DC, to attend a workshop with officials from NASA,NCATS (National Center for Advancing Translational Sciences), and other government officials for a “State-of-the-Science” meeting on 3D tissues and … Read more
- « Previous
- 1
- 2
- 3
- 4
- Next »
Explore
Get in Touch
Hesperos, Inc.
12501 Research Parway, Suite 100
Orlando, Florida 32826
(407) 900-5915
info@hesperosinc.com